Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ESMO open

Showing results (181-190 of 2,246) with videos related to

Pageof 225
Sort By:
ESMO Open|August 15, 2024
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trialsF Lordick, E Van Cutsem, K Shitara, et al.
ESMO Open|August 1, 2024
A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignanciesG Curigliano, M M Jimenez, T Shimizu, et al.
ESMO Open|August 1, 2024
Detecting pulmonary malignancy against benign nodules using noninvasive cell-free DNA fragmentomics assayS Xu, J Luo, W Tang, et al.
ESMO Open|January 18, 2023
Emerging targets for cancer treatment: S100A9/RAGEM Valiente, J M Sepúlveda, A Pérez
ESMO Open|December 25, 2022
Impact of EGFR<sup>A289T/V</sup> mutation on relapse pattern in glioblastomaA Noeuveglise, N Sarafan-Vasseur, L Beaussire, et al.
ESMO Open|December 25, 2022
Corrigendum to 'Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent': [ESMO Open volume 7 (2022) 100496]K Ribi, N Kalbermatten, M Eicher, et al.
ESMO Open|December 3, 2022
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancerB Waissengrin, T Zahavi, M Salmon-Divon, et al.
ESMO Open|December 3, 2022
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterationsK Murugesan, A Necchi, T C Burn, et al.
ESMO Open|December 4, 2022
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesotheliomaS Canova, G L Ceresoli, F Grosso, et al.
ESMO Open|July 1, 2022
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma IntergroupW Bruno, B Dalmasso, M Barile, et al.
Pageof 225

Showing results (181-190 of 2,246) with videos related to

Sort By:
Pageof 225
ESMO Open|August 15, 2024
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trialsF Lordick, E Van Cutsem, K Shitara, et al.
ESMO Open|August 1, 2024
A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignanciesG Curigliano, M M Jimenez, T Shimizu, et al.
ESMO Open|August 1, 2024
Detecting pulmonary malignancy against benign nodules using noninvasive cell-free DNA fragmentomics assayS Xu, J Luo, W Tang, et al.
ESMO Open|January 18, 2023
Emerging targets for cancer treatment: S100A9/RAGEM Valiente, J M Sepúlveda, A Pérez
ESMO Open|December 25, 2022
Impact of EGFR<sup>A289T/V</sup> mutation on relapse pattern in glioblastomaA Noeuveglise, N Sarafan-Vasseur, L Beaussire, et al.
ESMO Open|December 25, 2022
Corrigendum to 'Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent': [ESMO Open volume 7 (2022) 100496]K Ribi, N Kalbermatten, M Eicher, et al.
ESMO Open|December 3, 2022
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancerB Waissengrin, T Zahavi, M Salmon-Divon, et al.
ESMO Open|December 3, 2022
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterationsK Murugesan, A Necchi, T C Burn, et al.
ESMO Open|December 4, 2022
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesotheliomaS Canova, G L Ceresoli, F Grosso, et al.
ESMO Open|July 1, 2022
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma IntergroupW Bruno, B Dalmasso, M Barile, et al.
Pageof 225